BioSpace News Archive

People who are suffering from fibromyalgia pain are closer to a new option for treatment that targets their characteristically poor sleep quality.

LIXTE Biotechnology Holdings, Inc. ( Nasdaq: LIXT and LIXTW ) (“LIXTE” or the “Company”) today announced the signing of an exclusive patent license agreement with the National Institute of Neurological Disorders and Stroke (NINDS) and National Cancer Institute (NCI), each a component of the National Institute of Health (NIH).

J INTS BIO announced on the 26th of month that the Phase 1/2 clinical study of its Novel Oral 4th Generation EGFR TKI “JIN-A02" for the treatment of NSCLC has been accepted for poster presentation at the upcoming American Association for Cancer Research meeting to be held in San Diego USA from 5 to 10 April.

Bayer announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation for BAY 2927088 for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer whose tumors have activating HER2 mutations, and who have received a prior systemic therapy.

Microbix Biosystems Inc. announces the issuance of stock options under its shareholder-approved 2018 stock option plan, as part of its compensation programs to incentivize and retain its board of directors, executives, and managers.

Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the joint steering committee with its collaborator Neurocrine Biosciences has selected a lead development candidate in the Friedreich’s ataxia (FA) program.

Last Fall, Pharmascience, the largest Canadian-owned pharmaceutical company, announced a major $120 million sterile injectable manufacturing facility expansion at its Candiac site.

Aura Biosciences Inc. today announced that Elisabet de los Pinos, PhD, Chief Executive Officer, will participate in the following upcoming investor conferences.

Kura Oncology, Inc. today announced that the first patient has been dosed in KOMET-008, the Company’s Phase 1 trial of its menin inhibitor ziftomenib, in combination with gilteritinib, FLAG-IDA or LDAC for the treatment of NPM1-mutant or KMT2A-rearranged acute myeloid leukemia (AML).

Gemini Bioproducts, LLC today announced the launch of a new human AB serum product for the cell therapy and regenerative medicine markets.